Header Logo

Connection

Abdelrahmman Abukhdeir to Triazines

Back to Details
This is a "connection" page, showing publications Abdelrahmman Abukhdeir has written about Triazines.
Abdelrahmman Abukhdeir
Connection Strength
0.043
Triazines
  1. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clin Cancer Res. 2022 01 15; 28(2):249-254.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.